HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sisson, J. C. Articles by Lawson, S. Search for Related Content PubMed PubMed Citation Articles by Sisson, J. C. Articles by Lawson, S.

Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of ¹³¹I

Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan

There is no consensus on the amount of ¹³¹I for treatment of patients with well-differentiated thyroid carcinoma; usual amounts vary widely. Body retention of ¹³¹I has been shown to be a valuable index of radiation toxicity. If a broad range of body retentions occurs among patients, then high and low retentions will be a basis for modifying the usual prescriptions for ¹³¹I to ensure safety and increase efficacy. Methods: After withdrawal of thyroid hormone in 87 patients, the fractional retention of diagnostic ¹³¹I in each body was measured at 2 d by a scintillation probe. In 43 patients, the retention was measured 2 d after therapeutic ¹³¹I. Results: Diagnostic retention varied from 0.01 to 0.51, with a median of 0.15. These retentions did not correlate with any index of health, thyroid hormone, or carcinoma status. Seventeen patients, previously treated with ¹³¹I, exhibited a significantly lower mean retention. In 43 patients, retention of diagnostic ¹³¹I was highly correlated with retention of therapeutic ¹³¹I: diagnostic predicted therapeutic retention with a mean error of 0.04. In 10 patients receiving thyroxine, the mean retention of diagnostic ¹³¹I after recombinant human TSH (rhTSH) was strikingly lower, 0.06, with a range of 0.016–0.16. Conclusion: Body retentions of ¹³¹I are easily measured and vary considerably among patients. Because increased therapeutic ¹³¹I will impart greater irradiation of tumor, and body retention has been accepted as an index of toxicity from ¹³¹I, the use of body retention could enable prescriptions of therapeutic ¹³¹I that enable increased efficacy while ensuring safety. If tumor retention is not proportionally decreased with the body retention of ¹³¹I after rhTSH, then rhTSH may enable increased therapeutic efficacy.

Key Words: well-differentiated thyroid carcinoma • radioiodine • dosimetry • body retention

This article has been cited by other articles:

				H. Hanscheid, M. Lassmann, M. Luster, R. T Kloos, and C. Reiners Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma Endocr. Relat. Cancer, December 1, 2009; 16(4): 1283 - 1289. [Abstract] [Full Text] [PDF]

				P. W. Rosario, M. A. R. Borges, and S. Purisch Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782. [Abstract] [Full Text] [PDF]

				C. C. Travis and M. G. Stabin 131I Ablation Treatment in Young Females After the Chernobyl Accident J. Nucl. Med., October 1, 2006; 47(10): 1723 - 1727. [Abstract] [Full Text] [PDF]

				J. C. Sisson, A. M. Avram, S. A. Lawson, P. G. Gauger, and G. M. Doherty The So-Called Stunning of Thyroid Tissue J. Nucl. Med., September 1, 2006; 47(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				H. Hanscheid, M. Lassmann, M. Luster, S. R. Thomas, F. Pacini, C. Ceccarelli, P. W. Ladenson, R. L. Wahl, M. Schlumberger, M. Ricard, et al. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal J. Nucl. Med., April 1, 2006; 47(4): 648 - 654. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				K. Nakada, T. Ishibashi, T. Takei, K. Hirata, K. Shinohara, S. Katoh, S. Zhao, N. Tamaki, Y. Noguchi, and S. Noguchi Does Lemon Candy Decrease Salivary Gland Damage After Radioiodine Therapy for Thyroid Cancer? J. Nucl. Med., February 1, 2005; 46(2): 261 - 266. [Abstract] [Full Text] [PDF]